Status:
COMPLETED
Pulmonary Arterial Hypertension in Patients With Direct-Acting Antiviral Medications for Hepatitis C Virus Infection
Lead Sponsor:
Kantonsspital Olten
Conditions:
Pulmonary Artery Hypertension
Chronic Hepatitis c
Eligibility:
All Genders
18-90 years
Brief Summary
The purpose of this study is the evaluation of PAH in patients, who are treated with DAA medication for HCV infection.
Detailed Description
Study category and Rationale: This study is without any use of medication or investigations products, therefore this is a category A clinical trail. Background and Rationale: Pulmonary arterial hyper...
Eligibility Criteria
Inclusion
- Age 18-90 years
- Written informed consent
- New diagnosis of HCV, which requires the initiation of a DAA therapy
Exclusion
- Inability to provide informed consent
- Known diagnosis of pulmonary artery hypertension (PAH)
- Dyspnoe NYHA III-IV
- Mean pulmonary artery (PA) pressure (mPAP) of \>25 mmHg in the first TTE before start of DAA medication
Key Trial Info
Start Date :
July 1 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 1 2019
Estimated Enrollment :
49 Patients enrolled
Trial Details
Trial ID
NCT04094272
Start Date
July 1 2017
End Date
June 1 2019
Last Update
September 23 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Kantonsspital Olten
Olten, Switzerland, 4600